Información del artículo
El Texto completo está disponible en PDF
References
[1.]
G. Harris, B. Carey.
Researchers fail to reveal full drug pay.
The New York Times, (2008),
[2.]
Angell M. The New York Times Book Review. Volume 56, Number 1, January 15, 2009.
[3.]
G. Harris.
Leading psychiatrist didn’t report drug makers pay.
The New York Times, (2008),
[4.]
S. Brownslee.
Doctors without borders: Why you cannot trust medical journals anymore.
Washington Monthly, (2004),
[5.]
A. Bass.
Side effects: a prosecutor, a whistleblower, and a bestselling antidepressant on trial.
Algonquin Books of Chapel Hill, (2008),
[6.]
amednews.com; 23 Feb 2009.
[7.]
E.H. Turner, A.M. Matthews, E. Linardatos, R.A. Tell, R. Rosenthal.
Selective publication of antidepressant trials and its influence on apparent efficacy.
N Engl J Med, 358 (2008), pp. 252-260
[8.]
M. Petersen.
Our Daily meds: How the pharmaceutical companies transformed themselves into slick marketing machines and hooked the Nation on prescription drugs.
Sarah Crichton/Farrar, Straus and Giroux, (2008),
[9.]
C. Lane.
Shyness: how normal behavior became a sickness.
Yale University Press, (2007),
[10.]
M.E. Domino, M. Swartz.
Who are the new users of antipsychotic medications?.
Psychiatric Services, 59 (2008), pp. 507-514
[11.]
H.A. Huskamp.
Prices, profits and innovation: examining criticisms of new psychotropic drug's value.
Health Affairs, 25 (2006), pp. 635-646
[12.]
J. Weker.
Presented at APA symposium.
Psychiatric News, (2009), pp. 4
[13.]
Web MD. theheart. org, Abr 25, 2006.
[14.]
Institute of Medicine Report. Psychiatric News, June 5, 2009.
[15.]
Deal ends fraud case against UMDNJ. The Hartford Courant; June 10, 2009.
[16.]
J. Saiz Ruiz, A. Ibáñez Cuadrado, J. Peñalba Lopez.
Relación industria farmacéutica-investigación psiquiátrica.
Anales de Psiquiatría, 7 (1991), pp. 65-72
[17.]
L. Racionero.
El Mediterráneo y los Bárbaros del Norte.
2.ª, Plaza & Janes, (1985),
Copyright © 2009. SEP y SEPB